Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) EBIT Margin (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed EBIT Margin for 7 consecutive years, with 18409.09% as the latest value for Q1 2026.

  • For Q1 2026, EBIT Margin fell 1189010.0% year-over-year to 18409.09%; the TTM value through Mar 2026 reached 164794.12%, down 16432532.0%, while the annual FY2024 figure was 454.07%, 1000902.0% up from the prior year.
  • EBIT Margin hit 18409.09% in Q1 2026 for Barinthus Biotherapeutics, up from 2332400.0% in the prior quarter.
  • Across five years, EBIT Margin topped out at 117.37% in Q3 2022 and bottomed at 2332400.0% in Q2 2025.
  • Average EBIT Margin over 5 years is 237005.6%, with a median of 2489.61% recorded in 2022.
  • On a YoY basis, EBIT Margin climbed as much as 4820614bps in 2022 and fell as far as -166718862bps in 2022.
  • Barinthus Biotherapeutics' EBIT Margin stood at 388.62% in 2022, then plummeted by -1929bps to 7885.33% in 2023, then skyrocketed by 99bps to 62.66% in 2024, then tumbled by -3722042bps to 2332400.0% in 2025, then soared by 99bps to 18409.09% in 2026.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 18409.09%, 2332400.0%, and 6518.99% for Q1 2026, Q2 2025, and Q1 2025 respectively.